Skip to main content
Sinopharm Tech Holdings Limited logo

Sinopharm Tech Holdings Limited — Investor Relations & Filings

Ticker · 8156 ISIN · KYG2159V1418 HKEX Wholesale and retail trade
Open in API
Filings indexed 1,471 across all filing types
Latest filing 2025-06-05 Regulatory Filings
Country HK Hong Kong
Listing HKEX 8156

About Sinopharm Tech Holdings Limited

http://www.sinopharmtech.com.hk

Sinopharm Tech Holdings Limited is an investment holding company primarily engaged in the big health industry and pharmaceutical supply chain business. The company focuses on the trading and distribution of medical and related products, including Chinese patent medicines and health products, targeting the market in the PRC. It develops its supply chain operations using "Internet Plus" services, leveraging technology to provide value-added services to industry operators and product suppliers. The Group is also integrating AI analytics to enhance its operations within the healthcare sector.

Recent filings

Filing Released Lang Actions
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2025
Regulatory Filings Classification · 80% confidence The document is a “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” filed under Hong Kong Listing Rule 13.25C. It is a routine regulatory submission reporting movements in authorised share capital, issued shares, share options and convertibles for the month ended 31 May 2025. It is not an annual or interim financial report, not an earnings release, not a management presentation, and contains no single corporate action announcement—it is a periodic compliance return under HKEX rules. This does not neatly match more specific categories such as share issue/capital change (SHA) or capital/financing updates (CAP) since it is a standardized regulatory return. Therefore it falls under the general “Regulatory Filings” category.
2025-06-05 English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Governance Information Classification · 85% confidence The document is a formal announcement by Sinopharm Tech Holdings of its board composition, listing executive, non-executive, and independent directors along with committee memberships. It does not present financial results or meeting minutes, nor does it signal share transactions or legal actions. It focuses on the company’s board structure and governance framework (committee roles and functions), fitting the Governance Information category rather than an earnings, capital, or report publication announcement.
2025-06-02 English
APPOINTMENT OF EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES
Board/Management Information Classification · 92% confidence The document is a formal announcement by Sinopharm Tech Holdings Limited regarding the appointment of a new executive director and changes in its board committees, including biographical details, committee memberships, and compliance with listing rules. This clearly fits the definition of Board/Management Information, which covers announcements of changes in the company's board of directors or senior management. Therefore, it should be classified as MANG.
2025-06-02 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2025
Share Issue/Capital Change Classification · 76% confidence The document is the HKEX ‘Monthly Return for Equity Issuer and Hong Kong Depositary Receipts’ (Form FF301) covering movements in authorised/registered share capital, issued shares, share options, convertibles, and related capital reorganisation (sub-division of shares). It is a routine regulatory filing on share capital changes (including stock split, options, convertibles) rather than an earnings report or management commentary. This aligns with the Share Issue/Capital Change category (Code: SHA).
2025-05-08 English
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 30 JUNE 2024
Regulatory Filings Classification · 85% confidence The document is a supplemental announcement published on the HKEX relating to the company’s Annual Report for the year ended 30 June 2024, providing additional explanations on audit modifications and disclosures already included in the Annual Report. It is not the Annual Report itself (10-K), nor simply a notice of publication (RPA), nor does it fit any narrowly defined category such as dividends, M&A, board changes, or share transactions. Therefore, it should be classified under the fallback category Regulatory Filings (RNS).
2025-04-09 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2025
Share Issue/Capital Change Classification · 85% confidence The document is a FF301 Monthly Return under HKEX Listing Rules detailing movements in authorised/registered share capital, issued shares, share options, convertibles and confirmations under Main Board Rule 13.25C. It is clearly focused on share capital changes (sub-division of shares, conversion of loan into preference shares, movements in issued and treasury shares) rather than an earnings release or management report. It therefore most closely matches the “Share Issue/Capital Change” category.
2025-04-07 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.